Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 17CNS 9Lymphoid 8Head & Neck 8Gastrointestinal 7Other hematologic neoplasm 6Gynecologic 6Thoracic 5Breast 5Dermatologic 4Other solid neoplasm 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1NET 1Endocrine 1

Conditions

Pancreatic Neuroendocrine Tumors (pNET) 1

Interventions

lutetium Lu 177 dotatate 28Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4Capecitabine 4olaparib 3copper dotatate CU-64 3atezolizumab 3Temozolomide 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Watchful Waiting × NET × 1 year × Clear all
NCT07591493 2026-05-15

ADJUPANET

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Not yet recruiting
300 enrolled
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors (pNET)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡